United States securities and exchange commission logo





                          November 7, 2023

       Michael King, Jr.
       Chief Financial Officer
       SAB Biotherapeutics, Inc.
       2100 East 54th Street North
       Sioux Falls, South Dakota 57104

                                                        Re: SAB
Biotherapeutics, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed November 3,
2023
                                                            File No. 333-275319

       Dear Michael King:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Doris
Stacey Gama at 202-551-3188 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Brian Lee, Esq.